Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Oritavancin Diphosphate

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 98,243Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Orbactiv, 192564-14-0, Ly333328 diphosphate, Oritavancin phosphate, Oritavancin (diphosphate), Ly 333328 diphosphate
    Molecular Formula
    C86H103Cl3N10O34P2
    Molecular Weight
    1989.1  g/mol
    InChI Key
    PWTROOMOPLCZHB-BHYQHFGMSA-N
    FDA UNII
    VL1P93MKZN
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid;phosphoric acid
    2.1.2 InChI
    InChI=1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1
    2.1.3 InChI Key
    PWTROOMOPLCZHB-BHYQHFGMSA-N
    2.1.4 Canonical SMILES
    CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O
    2.1.5 Isomeric SMILES
    C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O
    2.2 Other Identifiers
    2.2.1 UNII
    VL1P93MKZN
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3''-(p-(p-chlorophenyl)benzyl)vancomycin

    2. Ly 333328

    3. Ly-333328

    4. Ly333328

    5. Orbactiv

    6. Oritavancin

    2.3.2 Depositor-Supplied Synonyms

    1. Orbactiv

    2. 192564-14-0

    3. Ly333328 Diphosphate

    4. Oritavancin Phosphate

    5. Oritavancin (diphosphate)

    6. Ly 333328 Diphosphate

    7. Oritavancin Diphosphate [usan]

    8. Vl1p93mkzn

    9. Ly-333328 Diphosphate

    10. Kimyrsa

    11. Nuvocid

    12. Oritavancin Diphosphate (usan)

    13. Unii-vl1p93mkzn

    14. Orbactiv (tn)

    15. Oritavancin Bisphosphate

    16. Chembl3989766

    17. Chebi:83305

    18. Hy-b1831a

    19. Dtxsid901027688

    20. Oritavancin Diphosphate [mi]

    21. Oritavancin Phosphate [mart.]

    22. Cs-5054

    23. Oritavancin Diphosphate [vandf]

    24. Oritavancin Diphosphate [who-dd]

    25. Ac-32605

    26. Oritavancin Diphosphately333328, Orbactiv

    27. Ly 333328 Pound>>oritavancin (phosphate)

    28. Oritavancin Diphosphate [orange Book]

    29. D05271

    30. Q27156742

    31. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin Phosphate(1:2)

    32. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin Phosphate(1:2) (salt)

    33. (4'r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)'-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin Phosphate (1:2) (salt)

    34. (4'r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)'-(p-(p-chlorophenyl)benzyl)vancomycin Phosphate (1:2) (salt)

    35. (4r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3-(p-(p-chlorophenyl)benzyl)vancomycin Diphosphate

    36. Vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-, Phosphate (1:2)

    37. Vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-, Phosphate (1:2) (salt)

    2.4 Create Date
    2011-08-02
    3 Chemical and Physical Properties
    Molecular Weight 1989.1 g/mol
    Molecular Formula C86H103Cl3N10O34P2
    Hydrogen Bond Donor Count26
    Hydrogen Bond Acceptor Count37
    Rotatable Bond Count19
    Exact Mass1986.517897 g/mol
    Monoisotopic Mass1986.517897 g/mol
    Topological Polar Surface Area717 Ų
    Heavy Atom Count135
    Formal Charge0
    Complexity3750
    Isotope Atom Count0
    Defined Atom Stereocenter Count22
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3
    4 Drug and Medication Information
    4.1 Drug Indication

    Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4. 4 and 5. 1).

    Consideration should be given to official guidance on the appropriate use of antibacterial agents.

    Treatment of acute bacterial skin and skin structure infections

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anti-Bacterial Agents

    Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 2D6 Inducers [MoA]; Cytochrome P450 3A4 Inducers [MoA]; Lipoglycopeptide Antibacterial [EPC]; Lipoglycopeptides [EXT]; Cytochrome P450 2C19 Inhibitors [MoA]
    5.3 ATC Code

    J01XA05